Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Y-mAbs Therapeutics Inc YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product... see more

Recent & Breaking News (NDAQ:YMAB)

Y-mAbs Announces Update on Omburtamab for DIPG

GlobeNewswire June 4, 2021

Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America

GlobeNewswire May 19, 2021

Y-mAbs Announces Update on SADA Technology

GlobeNewswire May 13, 2021

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

GlobeNewswire May 6, 2021

Y-mAbs to Announce First Quarter 2021 Financial and Operating Results on May 6, 2021

GlobeNewswire April 29, 2021

Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting

GlobeNewswire April 29, 2021

Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency

GlobeNewswire April 27, 2021

Y-mAbs Provides Regulatory Update on Omburtamab   

GlobeNewswire April 20, 2021

Y-mAbs Announces GPA33-SADA Data Presented at AACR

GlobeNewswire April 12, 2021

Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments

GlobeNewswire February 25, 2021

Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 22, 2021

Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021

GlobeNewswire February 19, 2021

Y-mAbs Announces Pricing of Public Offering of Common Stock

GlobeNewswire February 17, 2021

Y-mAbs Announces Proposed Public Offering of Common Stock

GlobeNewswire February 16, 2021

Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2021

Y-mAbs Announces Sale of Priority Review Voucher

GlobeNewswire December 28, 2020

Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China

GlobeNewswire December 18, 2020

Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe

GlobeNewswire December 18, 2020

Y-mAbs Announces Pipeline Update

GlobeNewswire December 16, 2020

Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO

GlobeNewswire December 9, 2020